GENE ONLINE|News &
BMS’s Once-Daily Plaque Psoriasis Treatment, Sotyktu, Gains FDA Approval to Rival Otezla
With solid data from two sets of clinical trials, the FDA approved Bristol Myers Squibb’s Sotyktu as a once-daily oral medication to treat moderate to severe plaque psoriasis. A day after the approval announcement, BMS posted more data supporting the drug’s promise from a long-term clinical trial demonstrating Sotyktu’s efficacy for up to two years with continuous treatment for plaque psoriasis.
Potential New Standard for Orally Administered Plaque Psoriasis Treatment
Plaque psoriasis is a prevalent, immune-mediated condition characterized by raised, inflamed, and scaly patches of skin covered with a silvery-white buildup of dead skin that may be painful or itchy for the patient. Approximately 7.5 million Americans have psoriasis, and about 90% of those suffer from plaque psoriasis. Nearly a quarter of Americans with plaque psoriasis deal with moderate to severe manifestations of the condition.
It's free! Log in now to read
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
